GlassScriptPhysician profile
Thomas J Czajkowski
NPI 1134136385
$12,616.94
in general payments reported to CMS, 2019-2025
40 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $1,143 · 2021: $1,998 · 2022: $1,688 · 2023: $2,075 · 2024: $2,429 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,418 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,418.40 |
| Education | $116.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,067.20 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $2,004.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,425.36 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,039.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $915.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $760.71 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $713.10 | 2019-2025 | Veozah |
| Pfizer INC. | $546.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $360.28 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.17 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $203.82 | 2019-2023 | |
| Horizon Therapeutics Plc | $198.00 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $183.42 | 2020-2023 | Xarelto |
| Glaxosmithkline, LLC. | $141.48 | 2022-2025 | Shingrix, Arexvy |
| Allergan, INC. | $132.48 | 2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $116.72 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $114.45 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $113.40 | 2022 | |
| Axsome Therapeutics, INC. | $111.01 | 2023-2025 | Auvelity, Sunosi |
| Esperion Therapeutics, INC. | $107.88 | 2021-2025 | Nexletol |
| Ardelyx, INC. | $99.46 | 2024-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $99.14 | 2020-2023 | |
| Almatica Pharma LLC | $96.56 | 2022-2025 | Loreev Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $94.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $92.22 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $91.64 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $68.92 | 2023-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $62.15 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $56.55 | 2023-2025 | Azmiro, Edarbyclor, Horizant |
| Gilead Sciences, INC. | $55.95 | 2019-2021 | |
| Phadia US INC. | $51.55 | 2021-2023 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $40.68 | 2021 | |
| Eisai INC. | $34.26 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.97 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $23.00 | 2023 | Quviviq |
| Therapeuticsmd, INC. | $20.53 | 2020 | |
| Currax Pharmaceuticals LLC | $15.80 | 2022 | |
| Vistapharm, INC. | $14.12 | 2021 | |
| Mannkind Corporation | $11.49 | 2020 | |
| Scilex Pharmaceuticals INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Czajkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.